Search
Paliroden
go.drugbank.com/drugs/DB05454InvestigationalIt is indicated for use in Alzheimer's Disease and Parkinson’s. … Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines.
Acadesine
go.drugbank.com/drugs/DB04944InvestigationalAcadesine has been granted Orphan Drug Designation for B-CLL in the EU. … Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing
Clenoliximab
go.drugbank.com/drugs/DB06241ExperimentalClenoliximab is a chimeric monoclonal antibody from _Macaca irus_ against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.
BF-1
go.drugbank.com/drugs/DB06029ExperimentalBF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.
Ranirestat
go.drugbank.com/drugs/DB05327InvestigationalIt has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy. … Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels
4-Hydroxytestosterone
go.drugbank.com/drugs/DB01485IllicitInvestigationalIt is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency. … [A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in
trans NV-04
go.drugbank.com/drugs/DB05843Experimentaltrans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.
Bepotastine
go.drugbank.com/drugs/DB04890ApprovedIt is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve. … Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the
Pyrazoloacridine
go.drugbank.com/drugs/DB12549InvestigationalPyrazoloacridine has been used in trials studying the treatment of Lung Cancer, Liver Cancer, Breast Cancer, Melanoma (Skin), and Metastatic Cancer, among others.
Categories: Compounds used in a research, industrial, or household settingMethdilazine
go.drugbank.com/drugs/DB00902ApprovedIt is used in the treatment of various dermatoses to relieve pruritus.